Seoul Bio Forum 2026

​Registration
Invitation Only · Limited Seats

​About Event

​The Seoul Bio Forum 2026 is a curated Korea–US life sciences forum hosted alongside the BIO International Convention in San Diego.

​Hosted by Chaperone Ventures and Seoul Bio Hub, and sponsored by Invest Seoul, this exclusive gathering brings together leading Korean biotech and pharmaceutical companies with U.S. venture capital firms, strategic investors, research institutions, and BD & licensing executives.

​The forum is designed to go beyond traditional showcase events — focusing on structured business development, investment conversations, and cross-border partnerships.

​What to Expect

​Korean Biotech Showcase
Presentations from high-growth Korean biotech companies across therapeutics, AI-driven drug discovery, and advanced healthcare technologies:

• ​TriOar (Series B)
  Making cancer drugs smarter and safer by masking antibody activity until they reach the tumor microenvironment.

• ​CuReVerse (Series B)
  Developing first-in-class small-molecule therapies for CNS disorders, including Alzheimer's disease and multiple sclerosis.

• ​Galux (Series B)
  Designing novel proteins using AI and physics-based platforms.

• ​VSPharmTech (Series B)
  Developing novel radiosensitizers that make cancer cells more susceptible to radiation therapy — with two FDA IND approvals already secured

• ​Astrogen (Pre-IPO)
  Developing therapeutics for autism spectrum disorders.

• ​Portrai (Series B)
  Leveraging AI and spatial biology to identify optimal cancer therapies.

• ​Connext (Series B)
  Developing protein-based therapeutics for musculoskeletal diseases.

• ​Elecell (Series A)
  Developing electroceutical devices for wound healing and tissue regeneration

• ​AAVATAR Therapeutics (Series A) Pioneering next-generation AAV gene therapy to treat rare and intractable diseases.

• ​ImpriMed (Series B) Using AI and live-cell testing to predict cancer drug response — from veterinary to human oncology.

• ​QGenetics (Series A) Developing a first-in-class oral small molecule that simultaneously treats osteoporosis and postmenopausal obesity.

• ​NeuroXT (Seed) Enabling biomarker-based Alzheimer's diagnosis and treatment prediction using MRI alone — no PET scan required.

​Market Entry & Regulatory Insights
Expert panels covering:

• ​U.S. regulatory pathways

• ​Investment in the US (New Company Creation included)

• ​Commercialization and market entry

​Partnering, Investor & Strategic Networking
Facilitated 1:1 meetings and curated roundtables connecting Korean innovators with U.S.-based venture capital and strategic partners.

​BD and licensing conversations with U.S. pharma companies, CROs, and research institutions.

​Panel Discussion

​The forum will feature a high-level panel discussion with distinguished experts & investors from the life sciences ecosystem:

• ​Debbie Lin, Ph.D. (TR.X Capital)

• ​Helen Siaw, Ph.D. (Aditum Bio)

• ​Michael Salgaller, Ph.D (NIH)

• ​Shaan Ghandi (Pfizer, PAVE)

• ​Moderated by David H. Crean, Ph.D.(Cardiff Advisory)

​Who Attends

• ​Korean Biotech Founders

• ​U.S Pharma Companies

• ​U.S. Venture Capital

• ​Strategic Investors

• ​BD & Licensing Executives

• ​Research Institutions

​Why This Event Matters

​This is not a traditional demo day.

​Seoul Bio Forum is a highly curated, invitation-only platform focused on:

• ​Real BD & licensing outcomes

• ​Cross-border investment opportunities

• ​Strategic partnerships between Korea and the U.S.

​By bringing together decision-makers from both ecosystems, the forum creates a high-signal environment for meaningful deal flow and long-term collaboration.